Maxwell D. Cummings

4.9k total citations
52 papers, 2.9k citations indexed

About

Maxwell D. Cummings is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Maxwell D. Cummings has authored 52 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Hepatology. Recurrent topics in Maxwell D. Cummings's work include Computational Drug Discovery Methods (9 papers), Hepatitis C virus research (9 papers) and Cancer-related Molecular Pathways (7 papers). Maxwell D. Cummings is often cited by papers focused on Computational Drug Discovery Methods (9 papers), Hepatitis C virus research (9 papers) and Cancer-related Molecular Pathways (7 papers). Maxwell D. Cummings collaborates with scholars based in United States, Belgium and Canada. Maxwell D. Cummings's co-authors include Randy J. Read, Renée L. DesJarlais, Edward P. Jaeger, Alan C. Gibbs, V. Mohan, James Brunton, Hong Ling, Glen D. Armstrong, Pierre Raboisson and Ann Vos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Maxwell D. Cummings

52 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maxwell D. Cummings United States 26 1.6k 681 577 498 457 52 2.9k
Priscilla L. Yang United States 26 2.3k 1.4× 889 1.3× 591 1.0× 329 0.7× 789 1.7× 48 4.6k
Magali Mathieu France 23 1.5k 1.0× 606 0.9× 220 0.4× 258 0.5× 202 0.4× 37 3.0k
Kent D. Stewart United States 34 1.3k 0.8× 559 0.8× 967 1.7× 333 0.7× 469 1.0× 91 3.1k
Tarek S. Mansour United States 43 2.2k 1.4× 590 0.9× 2.4k 4.2× 164 0.3× 436 1.0× 148 5.0k
Paul R. Caron United States 26 4.0k 2.5× 431 0.6× 265 0.5× 312 0.6× 485 1.1× 40 5.2k
Warren M. Kati United States 32 1.6k 1.0× 1.4k 2.0× 661 1.1× 219 0.4× 174 0.4× 81 3.5k
Paula M.D. Fitzgerald United States 22 1.6k 1.0× 1.0k 1.5× 635 1.1× 335 0.7× 317 0.7× 39 3.1k
Sanjeev Munshi United States 26 981 0.6× 446 0.7× 272 0.5× 346 0.7× 108 0.2× 41 2.1k
Noriyuki Habuka Japan 20 1.3k 0.8× 296 0.4× 378 0.7× 166 0.3× 485 1.1× 36 2.5k
Sherin S. Abdel‐Meguid United States 27 1.2k 0.8× 384 0.6× 444 0.8× 227 0.5× 302 0.7× 52 2.5k

Countries citing papers authored by Maxwell D. Cummings

Since Specialization
Citations

This map shows the geographic impact of Maxwell D. Cummings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxwell D. Cummings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxwell D. Cummings more than expected).

Fields of papers citing papers by Maxwell D. Cummings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxwell D. Cummings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxwell D. Cummings. The network helps show where Maxwell D. Cummings may publish in the future.

Co-authorship network of co-authors of Maxwell D. Cummings

This figure shows the co-authorship network connecting the top 25 collaborators of Maxwell D. Cummings. A scholar is included among the top collaborators of Maxwell D. Cummings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxwell D. Cummings. Maxwell D. Cummings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steeneck, Christoph, Christian Gege, Olaf Kinzel, et al.. (2020). Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach. Bioorganic & Medicinal Chemistry Letters. 30(12). 127174–127174. 14 indexed citations
2.
Sun, Weimei, Xuqing Zhang, Maxwell D. Cummings, et al.. (2020). Targeting Enteropeptidase with Reversible Covalent Inhibitors To Achieve Metabolic Benefits. Journal of Pharmacology and Experimental Therapeutics. 375(3). 510–521. 17 indexed citations
3.
Gege, Christian, M. Albers, Olaf Kinzel, et al.. (2020). Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt. Bioorganic & Medicinal Chemistry Letters. 30(12). 127205–127205. 10 indexed citations
4.
Lu, Tianbao, Peter J. Connolly, Ulrike Philippar, et al.. (2019). Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease. Bioorganic & Medicinal Chemistry Letters. 29(23). 126743–126743. 9 indexed citations
5.
Venkatesan, Hariharan, Maxwell D. Cummings, M. Albers, et al.. (2019). 3-Substituted Quinolines as RORγt Inverse Agonists. Bioorganic & Medicinal Chemistry Letters. 29(12). 1463–1470. 9 indexed citations
6.
Lenz, Oliver, Leen Vijgen, Jan Martin Berke, et al.. (2012). Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of Hepatology. 58(3). 445–451. 69 indexed citations
7.
Goethals, Olivia, Marcia Van Ginderen, Ann Vos, et al.. (2011). Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Research. 91(2). 167–176. 26 indexed citations
8.
Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Innentitelbild: Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target (Angew. Chem. 9/2010). Angewandte Chemie. 122(9). 1552–1552. 1 indexed citations
9.
Perera, Timothy, Peter King, Laurence Mévellec, et al.. (2008). JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models.. Cancer Research. 68. 4837–4837. 20 indexed citations
10.
Cummings, Maxwell D., Anthony Maxwell, & Renée L. DesJarlais. (2006). Processing of Small Molecule Databases for Automated Docking. Medicinal Chemistry. 3(1). 107–113. 15 indexed citations
11.
Parks, Daniel J., Louis V. LaFrance, Raul R. Calvo, et al.. (2006). Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design. Bioorganic & Medicinal Chemistry Letters. 16(12). 3310–3314. 57 indexed citations
12.
Subasinghe, Nalin L., Jeremy Travins, Hui Huang, et al.. (2006). A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorganic & Medicinal Chemistry Letters. 16(8). 2200–2204. 11 indexed citations
13.
Leonard, Kristi, Juan Marugán, Pierre Raboisson, et al.. (2006). Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorganic & Medicinal Chemistry Letters. 16(13). 3463–3468. 49 indexed citations
14.
Cummings, Maxwell D., Michael Farnum, & Marina I. Nelen. (2006). Universal Screening Methods and Applications of ThermoFluor®. SLAS DISCOVERY. 11(7). 854–863. 139 indexed citations
15.
Todd, Matthew J., Maxwell D. Cummings, & Marina I. Nelen. (2005). Affinity assays for decrypting protein targets of unknown function. Drug Discovery Today Technologies. 2(3). 267–273. 5 indexed citations
16.
Elkins, P.A., Ward W. Smith, Cheryl A. Janson, et al.. (2002). Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallographica Section D Biological Crystallography. 58(7). 1182–1192. 124 indexed citations
17.
Domagala, John M., Maxwell D. Cummings, Stephen J. Gracheck, et al.. (1998). Bacterial Two-Component Signalling as a Therapeutic Target in Drug Design. Advances in experimental medicine and biology. 456. 269–286. 9 indexed citations
18.
Arnason, Terra, et al.. (1996). The Tail of a Ubiquitin-conjugating Enzyme Redirects Multi-ubiquitin Chain Synthesis from the Lysine 48-linked Configuration to a Novel Nonlysine-linked Form. Journal of Biological Chemistry. 271(46). 28766–28771. 49 indexed citations
19.
Cummings, Maxwell D., et al.. (1995). Atomic solvation parameters in the analysis of protein‐protein docking results. Protein Science. 4(10). 2087–2099. 43 indexed citations
20.
Cummings, Maxwell D., et al.. (1995). Monte Carlo docking with ubiquitin. Protein Science. 4(5). 885–899. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Priscilla L. Yang Breakdown of academic impact, for papers by Magali Mathieu Breakdown of academic impact, for papers by Kent D. Stewart Breakdown of academic impact, for papers by Tarek S. Mansour Breakdown of academic impact, for papers by Paul R. Caron Breakdown of academic impact, for papers by Warren M. Kati Breakdown of academic impact, for papers by Paula M.D. Fitzgerald Breakdown of academic impact, for papers by Sanjeev Munshi Breakdown of academic impact, for papers by Noriyuki Habuka Breakdown of academic impact, for papers by Sherin S. Abdel‐Meguid
Rankless by CCL
2026